GW25-e3441 Analysis of SCN5A Mutation in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia  by Jinzhu, Hu & Kui, Hong
(P<0.01) and lowered collagen I/ III ratio (P <0.01), suggesting that Tongxinluo
improved myocardial collagen remodeling effectively.
Conclusions: Tongxinluo prevented NPY-induced cardiac microvascular spasm
effectively, and the mechanism was due to that Tongxinluo relieved the myocardial
inﬂammation, thinned the thickness of micrangium basement membrane and reversed
myocardial collagen remodeling.
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Objectives: The aim of this study was to investigate the changes of Urotensin II (UII)
and its receptor UT during myocardial ﬁbrosis in model of KK/Upj-Ay/J mice with
spontaneous type 2 diabetes, and evaluate whether blockade of UII would attenuate
cardiac ﬁbrosis in the model.
Methods: Diabetic KK/upj-AY/J and control C57BL/6J mice were fed with high fat
diet and normal chow diet respectively, for six weeks. Then, The KK/Upj - Ay/J mice
were randomly divided into two groups, diabetes mellitus (DM) group and diabetes +
urantide (DM + urantide) group, based on the level of fasting blood glucose. The DM
+ urantide mice were treated with urantide (30 mg kg-1day-1) by sc via an osmotic
mini-pump for 4 weeks. The water and food intake, weight were recorded. Fasting
blood glucose levels were assessed using blood collected from the tail vein.
Myocardial morphology was observed by Hematoxylin-Eosin and Masson staining.
The immunoreactivity of myocardial UII, UT, CD31, ﬁbroblast -speciﬁc protein
1 (FSP-1) were determined by immunohistochemistry. Plasma UII contents were
tested by radioimmunoassay. The protein expression of a-SMA, VE-cadherin and
P-smad2/3, CTGF were detected by western blot.
Results: There was a signiﬁcant increase in body weight, fasting blood glucose, water
intake and food intake in the DM group compared to the control group (P<0.01). The
DM group showed marked myocardial disarray and ﬁbrosis. Both UII and UT
immunoreactivity were increased in the DM group compared to the control group
(P<0.05). The ﬁbroblasts marker, FSP-1 immunoreactivity and a-SMA protein
expression were increased, while the endothelial marker, CD31 immunoreactivity and
VE-cadherin protein expression, were decreased, in the DM mice compared to control
mice (P<0.05). The smad2/3 Phosphorylation and CTGF protein expression in the
DM group were elevated than the controls (P<0.05). However, there is no signiﬁcant
difference in plasma UII levels between the DM and the controls (P>0.05). Impor-
tantly, treatment with Urantide signiﬁcantly reduced the body weight, fasting blood
glucose, water intake, and immunoreactivity of UII, UT, FSP-1, as well as protein
expression of a-SMA, P-samd2/3, CTGF, and alleviated myocardial disarray and
ﬁbrosis signiﬁcantly, while promoted CD31 immunoreactivity and VE-cadherin
expression signiﬁcantly (P<0.01 or P<0.05).
Conclusions: This study provided novel evidences that UII is involved in EndMT and
cardiac ﬁbrosis, and demonstrated that blockade of the UT receptor attenuated
myocardial ﬁbrosis in diabetes mellitus. It suggests that UII may represent a novel
therapeutic target in the treatment of diabetes mellitus.
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Objectives: Existing studies have shown that the expression of Omi/HtrA2, a pro-
apoptosis protein, is increased in the aging heart, while the release of cytochrome c is
involved in apoptosis during aging. The relationship between the increased expression
of Omi/HtrA2 and the release of cytochrome c in apoptosis of the aging heart,
however, has not been investigated. The present study was designed to determine
whether or not the increased expression of Omi/HtrA2 causes cardiomyocyte
apoptosis during aging via the release of cytochrome c.
Methods: Aging myocardial tissues were collected from aging rats (20-24 months),
and expression of Omi/HtrA2 was determined by Western blot analysis. The activities
of caspase-3 and -9 were chosen to reﬂect the level of apoptosis. H9C2 cells, a rat
embryonic cardiomyocyte line with over-expressed mitochondrial Omi/HtrA2, were
constructed. Both real-time PCR and Western blot technologies were used to identify
stably transfected Omi/HtrA2 cells. Mitochondrial and cytosolic fractions were
extracted by differential centrifugation, and the cytochrome c level in cytosolic
fraction was detected by Western blot.
Results: The results showed that expression of Omi/HtrA2 and the activities of cas-
pase-3 and -9 were signiﬁcantly increased in aging myocardial issue. Moreover, the
activities of caspase-3 and -9 in over-expressed Omi/HtrA2 cells were elevated. The
release of cytochrome c was increased, which was reversed by the speciﬁc Omi/HtrA2
inhibitor, ucf-101.C22 JACC Vol 64/16/Suppl C j OctobConclusions: These results demonstrate that increased expression of Omi/HtrA2 in
aging cardiomyocytes promotes apoptosis via release of cytochrome c.
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Objectives: Relaxin is a peptide hormone with potent cardiovascular effects, which
has been demonstrated to be safe and effective in acute heart failure in clinic trials.
However, effect of relaxin on heart failure with preserved ejection fraction (HFpEF) is
unknown. The aims of the study were to determine whether relaxin could improve the
diastolic function of HFpEF and to investigate the underling mechanisms.
Methods: In the present study, adenoviral vector expression relaxin-2 (Ad-RLN-2)
and GFP (Ad-GFP) were constructed. Pressure-overloaded rat model was established
by performing trans-aortic constriction (TAC) on SD rats, and 4 weeks later, echo-
cardiography and cardiac hemodynamics were performed. These TAC rats were
randomly assigned into 3 groups (TAC control group, without intramyocardial in-
jection; TAC+Ad-RLN-2, with intramyocardial injection of Ad-RLN-2; TAC+Ad-
GFP, with intramyocardial injection of Ad-GFP). And 12 days after intramyocardial
injection, diastolic and systolic function were determined by echocardiography and
cardiac hemodynamics. And then the rats were sacriﬁced, proteins and RNA were
extracted from left ventricles; Western Blotting and quantitative real-time PCR were
performed. Neonatal cardiomyocytes were isolated and were cultured with Ad-RLN-2
and Ad-GFP. And then laser confocal was used to detect the intracellular location of
phosphorylation Akt and PLB in neonatal cardiomyocytes.
Results: RLN-2 gene therapy was demonstrated to improve diastolic function by
echocardiographic and hemodynamic parameters. E/A ratio signiﬁcantly increased in
rats with RLN-2 gene delivery (1.860.26 vs 1.540.32 and 1.520.21, P<0.05 ),
and meanwhile, tissue Doppler image early (e’) and late (a’) velocity ratio at septal
part (e’/a’) was almost normalized to 1.200.49 (P<0.001), IVRT was signiﬁcantly
reduced (37.785.80ms vs 47.017.07ms and 45.857.44ms, P¼0.008 and 0.027,
respectively), dP/dtmin was lowered (-59561104 vs -48641171 and -45831123,
P<0.05 for both comparison), and Tau was reduced (17.42.4 vs 26.12.7 and
24.83.1, P<0.05 for both comparison) in rats with RLN-2 gene delivery when
compared with the TAC control and TAC+Ad-GFP groups. In rats injected with
Ad-RLN-2, phosphorylation level of nuclear-targeted Akt and phospholamban were
elevated, and SERCA2 activity was increased without changing SERCA2 level.
Conclusions: RLN-2 gene therapy was demonstrated to improve diastolic function.
The potential mechanism may be that RLN-2 gene transfer increased SERCA2
activity by activating phospholamban phosphorylaiton at both Ser16 and Thr17 sites
via activating nuclear-targeted Akt phosphorylation without changing the SERCA2
level.
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Objectives: Arrhythmogenic right ventricular cardiomyopathy/Dysplasia (ARVC/D)
is a genetically determined disorder, characterized by the two components: cardio-
myopathy and arrhythmia. To date, the molecular pathogenesis underly this phe-
nomenon is poorly understood. Whether the ion channel defect involved in the
ARVC/D is unknown. The aim of this study was systematically evaluate the sodium
channel variants in ARVC/D.
Methods: The patients according to the diagnostic guideline of ARVC/D revised in
2010 were collected. Genomic DNA was extracted from peripheral blood lympho-
cytes. All the exons and exon-intron boundaries of the SCN5A gene and desmosomal
genes known to be associated with ARVC/D, including DSC2, DSG2, DSP, JUP and
PKP2 were sequenced through the direct DNA sequencing.
Results: A total of 13 unrelated index patients were collected. A new missense
heterozygote mutation I137M in SCN5A gene was found in one proband 5. The
mutation sited at the exon 4 of the SCN5A and the S1 segment in Domain I of
Nav1.5, consisted of an C-to-G substitution at nucleotide site 411 (c.411C>G), which
predicted a substitution of isoleucine for methionine at codon site 137 (P. Ile137Met,
I137M). I137M was not detected in the 400 healthy control chromosomes from in-
dividuals of the same ethnic background, which indicated that this mutation was a
conservative site in SCN5A gene and the encoding protein - Nav1.5 may have a
functional defect.
Conclusions: Our study for the ﬁrst time systematically evaluates the sodium channel
variants in patients with ARVC/D and ﬁnds a new SCN5A mutation - I137M. The
result increases the insight of genetic pathogenesis in ARVC/D. The mutational
sodium channel may destroy the “desmosomal-related complex” and cause the genesis
of ARVC/D.er 16–19, 2014 j GW-ICC Abstracts/Basic and Translational Medicine
